Company intelligence / Profile preview

Fastox Pharma

Lausanne, Vaud, Switzerlandfastox.ch ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Fastox Pharma is a private Swiss biotechnology company developing products designed to enhance and prolong the effects of botulinum neurotoxin treatments in both aesthetic and therapeutic settings. The company is centered on its LAST platform, which aims to improve botulinum toxin performance without altering the core properties of the toxin itself. Fastox's lead development work appears to focus on FTP-501 and a related combination approach involving FTP-002/FTP-501 for severe glabellar lines. Publicly available sources indicate the company was founded in 2018, is based in Lausanne, and has been backed by Remora Biotech. Fastox has presented its technology at industry meetings and received recognition at the 2023 IMCAS Innovation Tank.

Therapeutic areas: OtherDermatology
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Fastox Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fastox Pharma.